In an email, James Heins, a spokesman for Purdue Pharma, the company that makes the narcotic painkiller OxyContin, said the pharmaceutical industry has been an important participant in IMMPACT's efforts to improve clinical trial procedures.
Date: Oct 07, 2013
Category: Health
Source: Google
FDA OxyContin decision: anti-abuse or anti-competition?
"That argument may sound good, but it doesn't hold waterwhen you look at the amount of effort that went intoreformulating this product," said Purdue spokesman James Heins.He said the company started to reformulate OxyContin to resistabuse starting in 2001, more than a decade
Date: Apr 19, 2013
Category: Health
Source: Google
Purdue Pharma LP undergoing children's trial of OxyContin
use of OxyContin in pediatric patients but will provide clinical information about the product's pharmacokinetics, safety and to a lesser extent efficacy, in pediatric patients to clinicians who may be, or may consider, using the product in children with moderate to severe chronic pain," James Heins
Purdue Pharma, which encountered abuse issues in the past in the marketing of OxyContin, has reformulated the product to successfully counterract improper use, said company spokesman James Heins, adding that it meets all FDA standards.
Date: Jul 05, 2012
Category: Health
Source: Google
Lured by Patent Protection, OxyContin Maker Tests Pain Drug in Kids
dministration's approval for pediatric use of OxyContin. The goal, said company spokesman James Heins, is to give more information on how the drug acts in the bodies of children who may need it for the overwhelming pain of conditions such as cancer, sickle cell anemia, severe burns and other trauma.